Terbinafine HCl 250 mg Tablet Under Fasting Conditions
Status:
Completed
Trial end date:
2002-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative bioavailability of the test formulation
of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis
Pharmaceuticals), under fasted conditions in healthy, non-tobacco using male and female adult
subjects.